Bausch + Lomb Corporation (BLCO)
NYSE · Healthcare · Medical Instruments & Supplies
$17.17+0.35%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $6.1B
- Forward P/E
- 15.5
- 52-week range
- $13.77 – $18.92
- 52-week change
- +16.71%
- EPS (trailing)
- −$0.49
- Analyst rating
- 2.3 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $5.1B (+6.47%)
- Net income
- −$360M
- Operating margin
- 2.2%
- Diluted EPS
- −$1.02
- Free cash flow
- −$66.0M
From the company’s annual report on SEC EDGAR.
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases.
Headquarters: Vaughan, Canada · 13,000 employees · bausch.com